Consultation on Proposal to Fund Lenvatinib for Kidney, Thyroid and Liver Cancers
Pharmac NZ are seeking feedback on a proposal to fund to lenvatinib, subject to eligibility criteria, for renal cell carcinoma (in combination with everolimus) as well as differentiated thyroid cancer, and advanced, unresectable hepatocellular carcinoma.
Access information about the consultation.
The consultation period ends at 4pm NZST on Wednesday 2 October 2024.